Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 11,061

Document Document Title
WO/2018/169252A1
The present invention relates to an N-benzyl-N-phenoxyl carbonyl-phenyl sulfonamide derivative, which inhibits PGE2 generation by means of inhibiting microsomal prostaglandin E2 synthase-1 (mPGES-1) and has enhanced activity, a method fo...  
WO/2018/170306A1
The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions fu...  
WO/2018/161892A1
A benzene sulfonamide compound having structural features of formula (I) or a pharmaceutically acceptable salt thereof, a preparation method therefor, and use thereof as an indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor. Experimental res...  
WO/2018/159640A1
Provided are: a curable composition including a salt compound provided with a) an organic anion of which the values of the Hansen solubility parameters δd, δp, and δH are respectively 16 or higher, in the range of 16-32 inclusive, and...  
WO/2018/157240A1
The disclosure relates to a compound of formula: (I) Several different uses of this compound are described for preparing different compounds. For example, this compound makes it possible to graft a fluorosulfonyl group on a molecule. A m...  
WO/2018/159650A1
The purpose of the present invention is to provide a compound which has a guanidine skeleton and inhibits the protease activity of MALT1 to exhibit a therapeutic effect or prophylactic effect on autoimmune diseases such as psoriasis. The...  
WO/2018/156297A1
The present invention related to novel sulfonamides or amides as TLR-4 antagonists, and pharmaceutical formulations containing the same and the methods of use thereof. Uses of the present novel sulfonamides or amides include, but are not...  
WO/2018/154519A1
The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compo...  
WO/2018/145620A1
Potent 5-HT2B antagonist of Formula (A), including stereochemically isomeric forms, and salts, hydrates, solvates thereof and their use wherein R1 to R4 and Ar have the meaning as defined herein. The present invention also relates to pro...  
WO/2018/145874A1
The invention relates to a compound of the formula (I) Ar(NHSO2Ar1)l(SO2NHAr1)m(NHC(O)NHAr2)n (I), wherein l and m independently of one another are 0, 1, 2, 3, and/or 4 and the sum of l+m is equal to or more than 1, n is 2, 3, 4, or 5, A...  
WO/2018/130625A1
The present invention relates to novel substituted benzene disulfonamides, as well as pharmaceutical compositions containing at least one of these substituted benzene disulfonamides together with at least one pharmaceutically acceptable ...  
WO/2018/129556A1
The present disclosure is directed to compounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-sta...  
WO/2018/128720A1
Provided herein are dUTPase inhibitors, compositions comprising such compounds and methods of using such compounds and compositions.  
WO/2018/117467A1
Disclosed in the specification is a method which selectively separates an R type enantiomer contained in a racemate (R/S=1/1) of N-[4-(1-amino-ethyl)-2,6-difluoro-phenyl]-methanesulfonamide , and then can convert the same back into the r...  
WO/2018/118827A1
The present invention is directed to compounds of Formula I, pharmaceutical compositions comprising the same, and their use in the inhibition of HIV protease, the inhibition of HIV replication, the prophylaxis of infection by HIV, the tr...  
WO/2018/107289A1
Compounds described herein are inhibitors of retinoic acid inducible P450 (CYP26) enzymes, and are useful for treating diseases that are responsive to retinoids. Certain compounds have retinoid activity, are resistant to CYP26-mediated c...  
WO/2018/104307A1
Substituted aromatic sulfonamides of formula (I), pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a d...  
WO/2018/104305A1
Substituted aromatic sulfonamides of formula (I) which are antagonists or negative allosteric modulators of P2X4, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing a ph...  
WO/2018/103583A1
Inhibitors with anti-inflammatory agents are provided, as are methods of using the analogs to inhibit inflammation and prevent or treat diseases and conditions associated with inflammation, such as multiple sclerosis and autoinflammatory...  
WO/2018/102419A1
The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.  
WO/2018/095488A1
The invention relates to sulfobetaine compounds, a process for synthesizing same, and the uses of sulfobetaine compounds for synthesizing antimicrobial materials, antistatic materials, antifouling materials, printing inks, surface-active...  
WO/2018/098209A1
Provided herein are dUTPase inhibitors, compositions comprising such compounds and methods of using such compounds and compositions.  
WO/2018/093694A1
Disclosed are compounds of Formula A, or a salt thereof: Formula (A), wherein: Het, Q and R1A to R4A are defined herein, which compounds have properties for blocking Nav 1.7 ion channels found in peripheral and sympathetic neurons. Also ...  
WO/2018/086531A1
Disclosed are a series of sulfonamides compounds, represented by general formulas (I) and (II), serving as cccDNA inhibitors, and tautomers or pharmacologically acceptable salts thereof.  
WO/2018/086507A1
The invention discloses a naphthalene sulfonamide type compound, a preparation method thereof and an application thereof for regulating plant growth activity. A general formula of a structure of the naphthalene sulfonamide type compound ...  
WO/2018/085171A1
The present disclosure relates to compounds of formula (I) that are useful as modulators of α7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly ...  
WO/2018/085170A1
The present disclosure relates to compounds of formula (I) that are useful as modulators of α7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly ...  
WO/2018/078657A1
The present invention discloses a simple, economic, consistent, commercially viable and industrially applicable process for preparation of Glipizide in high yield and highly pure Glipizide having purity more than 95%, preferably more tha...  
WO/2018/072024A1
The invention relates to methods for the production of sulphamic acid derivatives, for example, halogenated derivatives and the salts thereof, metallic or organic, are described. The present application also relates to the resulting sulp...  
WO/2018/068295A1
Substituted aryl and heteroaryl ether compounds of the Formula (I) and pharmaceutically acceptable salts thereof, wherein X, R 1, R 2, R 3, L, R 4, L 1, Q, and R 5 are as defined herein. These compounds and pharmaceutically acceptable co...  
WO/2018/071327A1
This disclosure relates to the field of molecules having pesticidal utility against pests in Phyla Arthropoda, Mollusca, and Nematoda, processes to produce such molecules, intermediates used in such processes, pesticidal compositions con...  
WO/2018/059491A1
Disclosed are an ionic liquid compound, an ionic liquid polymer prepared from the ionic liquid compound, a solid state electrolyte containing the polymer, an electrode binder for a battery, and a battery. Specifically, provided are an io...  
WO/2018/062799A1
Disclosed in the present specification is a method capable of preparing N-[4-[(1R)-1-[[(R)-(1,1-dimethylethyl)sulfinyl]amino]ethyl]- 2,6-difluorophenyl]-methanesulfonamide (INT028-2) with high optical purity, through the selection of Ell...  
WO/2018/053080A1
Acute kidney injury (AKI) is often associated with damage to remote organs, such as lungs or heart. AKI induces kidney tubular necrosis as well as NETosis, programmed neutrophil death leading to neutrophil extracellular traps (NETs). His...  
WO/2018/050631A1
The present invention relates to novel compounds of general formula (I) wherein the groups X, and R1 to R4 have the meanings given in the description and claims, process for preparing these compounds and their use as for treating, preven...  
WO/2018/048675A1
Described are compounds of the formula: wherein RAryl is an aryl group; R1 is a linear or branched C2-C40 hydrocarbyl group; R2 is a C1-C4 alkyl; Rfis a perfluorinated group of having an average of 3 to 5 carbon atoms; and subscript x is...  
WO/2018/044663A1
Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: Formula (I). Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated dis...  
WO/2018/043400A1
A compound represented by formula (I) or a salt thereof. In formula (I), each of R1 and R4 independently represents a hydrogen atom, an unsubstituted or substituted C1-6 alkyl group or the like; R2 represents a hydrogen atom, an unsubsti...  
WO/2018/042894A1
Provided is a novel m-phenylenediamine compound which is useful as a starting material for the synthesis of a functional polymer compound, or the like. Also provided is a method for producing a polymer compound, which uses this novel m-p...  
WO/2018/029150A1
The invention relates to compounds acting as agonists of G-protein coupled receptor 120 (GPR120) and/or 40 (GPR40), and having formula (I). Said compounds are useful in the treatment of diseases or disorders modulated by GPR120 and/or GP...  
WO/2018/029699A1
The Present invention relates to solid state forms of (2E)-N-hydroxy-3-[3-(N-phenyl sulfamoyl)phenyl]prop-2-enamide represented by the following structural formula-1 and process for the preparation thereof.  
WO/2018/018863A1
Disclosed are a mild and efficient preparation method for an α-acyloxy alkenyl amide compound and a use thereof in the synthesis of an amide and a polypeptide. The α-acyloxy alkenyl amide compound is obtained by an addition reaction of...  
WO/2018/018091A1
The present invention relates to compounds and their use in the prophylactic and/or therapeutic treatment of pulmonary fibrosis and/or related conditions.  
WO/2018/021185A1
[Problem] To provide a morphology for storage and the like of a sulfonimide which was difficult to produce by conventional methods, which has a reduced content of halide, and which has polymerizable functional groups having improved spon...  
WO/2018/020406A1
The present invention relates to the polymorphic forms of Belinostat. The invention also relates to the process for the preparation of the polymorphic forms of Belinostat. This invention further relates to pharmaceutical composition of s...  
WO/2018/015178A1
The invention relates to a color developer of the formula (I), wherein m and n independently of one another are ≥ 1, Ar1 is an unsubstituted or substituted (hetero) aromatic radical, Ar2 is an unsubstituted or substituted phenyl radica...  
WO/2018/015493A1
A metal complex has the general formula (I), in which: R-Z is a HDAC inhibitor in which Z a terminal hydroxamate group; M is a redox active metal; n+ is the positive charge on the complex cation; Bn- is a balancing counterion; Z binds to...  
WO/2017/219935A1
The present invention discloses a biaryl urea RORγt inhibitor, and specifically relates to a biaryl urea derivative, as represented by formula I, with an RORγt inhibiting activity, and a manufacturing method thereof, and a pharmaceutic...  
WO/2017/214725A1
A method of screening a compound or a composition for use in modulating opioid withdrawal symptoms in a mammal. The method comprises the steps of: selecting a group of test animals; separating the group into two subgroups; inducing panne...  
WO/2017/212289A1
The present invention relates to a method of reducing, cleaving and/or coupling at least one C=O, C-O, C=C or C=N bond of a compound, using a reagent comprising a stannyl cation.  

Matches 1 - 50 out of 11,061